Education
About Us
Working with TipRanks
Follow Us
Abbvie (DE:4AB)
:4AB
4AB Stock Chart & Stats
Day’s Range― - ―
52-Week Range€141.98 - €204.45
Previous CloseN/A
Volume1.25K
Average Volume (3M)933.00
Market Cap
€261.88B
Enterprise Value€376.68B
Total Cash (Recent Filing)$41.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)69.0
Beta0.23
Next Earnings
Apr 25, 2025EPS Estimate
2.06Last Dividend Ex-Date
Apr 15, 2025Dividend Yield3.64%
Share Statistics
EPS (TTM)2.20
Shares Outstanding1,768,978,300
10 Day Avg. Volume1,628
30 Day Avg. Volume933
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.58
Price to Cash Flow (P/CF)13.20
P/FCF Ratio12.00
Enterprise Value/Market Cap1.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.55
Enterprise Value/Ebitda20.75
Forecast
1Y Price Target
€184.69Price Target Upside21.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
---
Bulls Say, Bears Say
Bulls Say
Immunology Franchise GrowthThe strong growth algorithm for commercial powerhouses Skyrizi and Rinvoq, the two key pillars of the company's core Immunology franchise, is driving the company's topline.
Obesity Market ExpansionABBV announced a licensing agreement to co-develop a treatment for obesity, which indicates a strategic expansion into this market.
Stock PerformanceAbbVie’s share price has been the best performer in US/EU large pharma, up 22% ytd.
Bears Say
Aesthetics Franchise ChallengesChallenging conditions are expected to continue for the Aesthetics franchise due to sluggish macro-economic dynamics and suppressed consumer sentiment.
Competitor And Commercialization RisksIntensifying competitive headwinds in the injectable aesthetics market and potential commercialization risks around BonT/E pose challenges.
Pipeline And Portfolio SetupNo major pipeline catalysts are ahead, creating a tougher near-term setup for Abbvie's portfolio.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.07% Insiders
21.40%
Mutual Funds
0.79% Other Institutional Investors
56.18% Public Companies and
Individual Investors
4AB FAQ
What was Abbvie’s price range in the past 12 months?
Abbvie lowest stock price was €141.98 and its highest was €204.45 in the past 12 months.
What is Abbvie’s market cap?
Abbvie’s market cap is €261.88B.
When is Abbvie’s upcoming earnings report date?
Abbvie’s upcoming earnings report date is Apr 25, 2025 which is in 2 days.
How were Abbvie’s earnings last quarter?
Abbvie released its earnings results on Jan 31, 2025. The company reported €1.899 earnings per share for the quarter, beating the consensus estimate of €1.86 by €0.04.
Is Abbvie overvalued?
According to Wall Street analysts Abbvie’s price is currently Undervalued.
Does Abbvie pay dividends?
Abbvie pays a Quarterly dividend of €5.547 which represents an annual dividend yield of 3.64%. See more information on Abbvie dividends here
What is Abbvie’s EPS estimate?
Abbvie’s EPS estimate is 2.06.
How many shares outstanding does Abbvie have?
Abbvie has 1,768,978,300 shares outstanding.
What happened to Abbvie’s price movement after its last earnings report?
Abbvie reported an EPS of €1.899 in its last earnings report, beating expectations of €1.86. Following the earnings report the stock price went up 7.236%.
Which hedge fund is a major shareholder of Abbvie?
Currently, no hedge funds are holding shares in DE:4AB
---
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€184.69 (21.19% Upside)
€184.69 (21.19% Upside)
Blogger Sentiment
Bullish
DE:4AB Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $69.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.96%
12-Months-Change
Fundamentals
Return on Equity
61.94%
Trailing 12-Months
Asset Growth
0.33%
Trailing 12-Months
Company Description
Abbvie
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
---
4AB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
AbbVie demonstrated strong financial performance in 2024 with notable growth in its ex-Humira platform and advancements in neuroscience and oncology. However, challenges persist with Humira revenue erosion and the aesthetic market facing economic headwinds. Overall, the company is poised for robust growth in 2025 despite these challenges.Read More>---
4AB Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
---
4AB Stock 12 Month Forecast
Average Price Target
€184.69
▲(21.19% Upside)
Technical Analysis
Best Analysts Covering 4AB
1 Year
1 Year Success Rate
35/41 ratings generated profit
1 Year Average Return
+20.62%
assigned a buy rating 3 months ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 85.37% of your transactions generating a profit, with an average return of +20.62% per trade.
---